4.0 Article

Recurrent Macrophage Activation Syndrome Associated With Heterozygous Perforin W374X Gene Mutation in a Child with Systemic Juvenile Idiopathic Arthritis

Journal

JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY
Volume 35, Issue 5, Pages E205-E208

Publisher

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/MPH.0b013e31827b4859

Keywords

macrophage activation syndrome; MAS; systemic juvenile idiopathic arthritis; sJIA; perforin gene; W374X mutation; hemophagocytic lymphohistiocytosis; familial HLH

Funding

  1. TUBITAK [105S386 (SBAG-3193)]
  2. TUBA

Ask authors/readers for more resources

Background: Recurrent macrophage activation syndrome (MAS) is rarely reported. Aim: To describe recurrent MAS in a 2.5-year-old girl with systemic juvenile idiopathic arthritis and heterozygous perforin mutation, which may have a role in the patient's first recurrence despite use of the HLH-2004 treatment protocol. Observations: In the presented case, MAS was initially controlled after the addition of etoposide to the treatment regimen. However, recurrence occurred 6.5 months after cessation of the HLH-2004 protocol. Subsequent recurrences may have occurred because of the family's noncompliance with treatment. Conclusions: The patient's extremely high serum ferritin level (267,054 ng/mL) and the recurrent course of MAS may have been because of the coexistence of juvenile idiopathic arthritis and heterozygous perforin W374X mutation. We suggest to search for mutations in HLH genes in recurrent MAS cases.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.0
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Infectious Diseases

Frailty and sarcopenia among Turkish people aged 40 and above living with HIV

Mehdi Houssein, Ahmet Cagkan Inkaya, Cafer Balci, Mert Esme, Meliha Cagla Sonmezer, Serhat Unal, Meltem Gulhan Halil

Summary: Frailty is common among Turkish people living with HIV and is associated with higher morbidity and mortality rates.

HIV MEDICINE (2022)

Article Public, Environmental & Occupational Health

Is there still a room for improvement in antimicrobial use in a setting where use of broad-spectrum antibiotics require approval of an infectious diseases physician?

Gokhan Metan, Omrum Uzun, Gulcin Telli Dizman, Meliha Cagla Sonmezer, Ahmet Cagkan Inkaya, Gulsen Hazirolan, Murat Akova, Serhat Unal

INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY (2022)

Article Medicine, General & Internal

Integrase inhibitor-based regimens are related to favorable systemic inflammatory index and platecrit scores in people living with HIV (PLWH) up to 2 years

Ezgi Aysu Sahin, Deniz Mavi, Emre Kara, Meliha Cagla Sonmezer, Ahmet Cagkan Inkaya, Serhat Unal

Summary: This study analyzed the changes in inflammatory markers among people living with HIV (PLWH) treated with different antiretroviral regimens over a period of two years. The results showed that treatment with integrase inhibitors was associated with a favorable inflammatory marker profile among PLWH in the two-year follow-up. These favorable inflammatory characteristics may contribute to the prevention of non-communicable diseases (NCD) among PLWH.

POSTGRADUATE MEDICINE (2022)

Article Immunology

Relative Vaccine Effectiveness of the Third Dose of CoronaVac or BNT162b2 Following a Two-Dose CoronaVac Regimen: A Prospective Observational Cohort Study from an Adult Vaccine Center in Turkey

Meliha Cagla Sonmezer, Gulcin Telli Dizman, Enes Erul, Taha Koray Sahin, Tugba Saricaoglu, Alparslan Alp, Mine Durusu Tanriover, Omrum Uzun, Serhat Unal, Murat Akova

Summary: Vaccines, such as CoronaVac and BNT162b2, have shown effectiveness in preventing symptomatic COVID-19 cases. The third dose of these vaccines can provide further protection against severe COVID-19. It is important to prioritize the administration of third-dose boosters as an effective strategy in combating the pandemic.

VACCINES (2022)

Review Microbiology

Peptide Based Vaccine Strategies

Semra Aydin, Gamze Varan, Serhat Unal

Summary: Synthetic peptides are useful tools for studying proteins and developing vaccine candidates. However, they have low immunogenicity capacities and are susceptible to enzymatic degradation. By using a multiepitope approach and an appropriate adjuvant/carrier system, the immunogenicity capacities of synthetic peptides can be enhanced.

FLORA INFEKSIYON HASTALIKLARI VE KLINIK MIKROBIYOLOJI DERGISI (2022)

Meeting Abstract Oncology

Immunogenicity of two doses of inactive COVID-19 vaccine and third booster dose mRNA vaccine in patients with cancer receiving active systemic therapy

D. C. C. Guven, F. G. Gulbahce Incesu, H. C. Yildirim, E. Erul, E. Chalabiyev, B. Y. Aktas, D. Yuce, Z. Arik, S. Kilickap, S. Aksoy, M. Erman, K. M. Hayran, S. Unal, A. Alp, O. Dizdar

ANNALS OF ONCOLOGY (2022)

Article Medicine, General & Internal

Community-acquired pneumonia - An EFIM guideline critical appraisal adaptation for internists

Ahmet Gorkem Er, Alberto Antonio Romero Alonso, Ignacio Marin-Leon, Abdullah Sayiner, Stefano Bassetti, Kutay Demirkan, Patrick Lacor, Hartmut Lode, Wiktoria Lesniak, Mine Durusu Tanriover, Ali Fuat Kalyoncu, Nicolas Merchante, Serhat Unal

Summary: This document provides a simple and reliable updated guide for clinical decision-making in the management of complex patients with multimorbidity and CAP in the real-life setting.

EUROPEAN JOURNAL OF INTERNAL MEDICINE (2022)

Article Oncology

Immunogenicity of two doses of inactive COVID-19 vaccine and third booster dose mRNA vaccine in patients with cancer receiving active systemic therapy

Deniz Can Guven, Fatma Gul Gulbahce Incesu, Hasan Cagri Yildirim, Enes Erul, Elvin Chalabiyev, Burak Yasin Aktas, Deniz Yuce, Zafer Arik, Saadettin Kilickap, Sercan Aksoy, Mustafa Erman, Kadir Mutlu Hayran, Serhat Unal, Alpaslan Alp, Omer Dizdar

Summary: This study aimed to evaluate the seroconversion rates after two doses of inactive COVID-19 vaccine (CoronaVac) and the benefit of a third dose mRNA vaccine booster in patients with cancer receiving active treatment. The results showed that cancer patients had lower antibody levels and seropositivity rates after two doses of CoronaVac compared to the control group. However, the seroconversion rate significantly increased and antibody titers improved after administering a third dose of an mRNA vaccine. Administering a third dose of mRNA vaccine can effectively improve the immunogenicity of CoronaVac in cancer patients receiving active treatment.

INTERNATIONAL JOURNAL OF CANCER (2023)

Article Infectious Diseases

Prevalence of Common Human Coronaviruses (NL63, 229E, and OC43) in Adults before the COVID-19 Pandemic: a Single-Center Study from Turkey, 2015-2020

Meliha Cagla Sonmezer, Taha Koray Sahin, Enes Erul, Gulcin Telli Dizman, Ahmet Cagkan Inkaya, Alparslan Alp, Sehnaz Alp, Serhat Unal

Summary: This study investigated the burden of common human coronaviruses (HCoVs) in a hospital setting over a five-year period. The results showed that HCoVs can cause respiratory tract infections, and co-infection with rhinovirus was the most common. These findings have important implications for the control and prevention of respiratory infections.

JAPANESE JOURNAL OF INFECTIOUS DISEASES (2023)

Article Immunology

Knowledge and Attitudes of Turkish Physicians towards Human Monkeypox Disease and Related Vaccination: A Cross-Sectional Study

Taha Koray Sahin, Enes Erul, Melek Seren Aksun, Meliha Cagla Sonmezer, Serhat Unal, Murat Akova

Summary: This study surveyed 283 physicians in Turkey about their knowledge, attitude, concerns, and vaccine acceptance for monkeypox. The results showed that 32.5% of the physicians had a good level of knowledge and 31.4% planned to have the monkeypox vaccine. Female physicians and older individuals were more likely to be knowledgeable about monkeypox. Physicians from internal medicine divisions, those who learned about monkeypox during medical school or residency, and those previously exposed to COVID-19 had a higher knowledge score of monkeypox. Physicians with a good knowledge score were more worried about monkeypox compared to COVID-19.

VACCINES (2023)

Article Oncology

Impact of pharmacist-led educational intervention on pneumococcal vaccination rates in cancer patients: a randomized controlled study

Nesligul Ozdemir, Burak Y. Y. Aktas, Ahmet Gulmez, Ahmet C. C. Inkaya, Aygin Bayraktar-Ekincioglu, Saadettin Kilickap, Serhat Unal

Summary: This study aimed to assess the impact of clinical pharmacists' education on pneumococcal vaccination rate in cancer patients. The results showed that education provided by clinical pharmacists significantly increased the pneumococcal vaccination rate in cancer patients.

SUPPORTIVE CARE IN CANCER (2023)

Article Microbiology

Investigation of the Frequency of Neisseria gonorrhoeae, Chlamydia trachomatis, Trichomonas vaginalis and Mycoplasma genitalium in Men Living with HIV in Terms of Sociodemographic Characteristics and Behavioral Risk Factors

Caglayan Merve Ayaz, Nesrin Damla Karakaplan, Ahmet Cagkan Inkaya, Banu Cakir, Serhat Unal, Pinar Zarakolu

Summary: The aim of this study was to investigate the frequency of Neisseria gonorrhoeae, Chlamydia trachomatis, Trichomonas vaginalis and Mycoplasma genitalium in men living with HIV. The study found that young age, having multiple partners, drug use, and exchanging sex for money/drugs were associated with STI infection.

MIKROBIYOLOJI BULTENI (2023)

Article Critical Care Medicine

Efficacy and safety of baricitinib in hospitalized adults with severe or critical COVID-19 (Bari-SolidAct): a randomised, double-blind, placebo-controlled phase 3 trial

Marius Troseid, Jose R. Arribas, Lambert Assoumou, Aleksander Rygh Holten, Julien Poissy, Vida Terzic, Fulvia Mazzaferri, Jesus Rodriguez Bano, Joe Eustace, Maya Hites, Michael Joannidis, Jose-Artur Paiva, Jean Reuter, Isabel Puentmann, Thale D. J. H. Patrick-Brown, Elin Westerheim, Katerina Nezvalova-Henriksen, Lydie Beniguel, Tuva Borresdatter Dahl, Maude Bouscambert, Monika Halanova, Zoltan Peterfi, Sotirios Tsiodras, Michael Rezek, Matthias Briel, Serhat Unal, Martin Schlegel, Florence Ader, Karine Lacombe, Cecilie Delphin Amdal, Serge Rodrigues, Kristian Tonby, Alexandre Gaudet, Lars Heggelund, Joy Mootien, Asgeir Johannessen, Jannicke Horjen Moller, Beatriz Diaz Pollan, Anders Aune Tveita, Anders Benjamin Kildal, Jean-Christophe Richard, Olav Dalgard, Victoria Charlotte Simensen, Aliou Balde, Lucie de Gastines, Marta del Alamo, Burc Aydin, Fridtjof Lund-Johansen, Mary-Anne Trabaud, Alpha Diallo, Bente Halvorsen, John-Arne Rottingen, Evelina Tacconelli, Yazdan Yazdanpanah, Inge C. Olsen, Dominique Costagliola

Summary: The study conducted a placebo-controlled trial of baricitinib in severe/critical COVID cases. The results showed that baricitinib did not reduce mortality within 60 days, and there may be safety risks in vaccinated participants, which require further investigation.

CRITICAL CARE (2023)

Article Medicine, General & Internal

Remdesivir treatment for patients with moderate to severe COVID-19

Imran Hasanoglu, Rahmet Guner, Ilhami Celik, Fikret Kanat, Ayse Batirel, Gulcin Telli Dizman, Esma Eren, Dilek Yildiz Sevgi, Ilkay Bozkurt, Kadriye Kart Yasar, Sevtap Senoglu, Esra Kazak, Ridvan Karaali, Aysel Celikbas, Husnu Pullukcu, Arif Atahan Cagatay, Serhat Unal, Sebnem Erdinc, Fehmi Tabak, Ahmet Gul, Emine Alp

Summary: This study aimed to evaluate risk factors for mortality and prognosis of adult moderate/severe COVID-19 patients treated with remdesivir, and safety and tolerability of 5 days of remdesivir treatment. The study found that remdesivir is a safe and well-tolerated drug, and older age, low SpO(2) level on admission, tachycardia, and ICU admission are independently associated with increased mortality among patients with moderate/severe COVID-19 receiving remdesivir treatment.

TURKISH JOURNAL OF MEDICAL SCIENCES (2022)

Article Medicine, General & Internal

Pertussis prevalence among adult patients with acute cough

Ahmet Ilbay, Mine Durusu Tanriover, Iskin Pinar Zarakol, Ezgi Caliskan Guzelce, Hatice Bolek, Serhat Unal

Summary: This study found a prevalence of 3.5% for pertussis in adults, which may be easily overlooked or misdiagnosed. Patients with pertussis commonly experienced paroxysmal cough with an average duration of 20 days. These findings indicate that pertussis remains a health problem in adults, suggesting that childhood vaccination may not be sufficient to prevent infection in adults.

TURKISH JOURNAL OF MEDICAL SCIENCES (2022)

No Data Available